CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

N/A

Manufactured by Actavis Pharma, Inc.

933 FDA adverse event reports analyzed

Last updated: 2026-04-15

About CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Actavis Pharma, Inc.. The most commonly reported adverse reactions for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE include CHRONIC KIDNEY DISEASE, FATIGUE, RENAL FAILURE, ACUTE KIDNEY INJURY, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE.

Top Adverse Reactions

CHRONIC KIDNEY DISEASE55 reports
FATIGUE37 reports
RENAL FAILURE34 reports
ACUTE KIDNEY INJURY24 reports
DRUG INEFFECTIVE23 reports
NAUSEA23 reports
DYSPNOEA21 reports
RASH20 reports
DIZZINESS18 reports
PAIN17 reports
DEATH15 reports
HEADACHE15 reports
CONDITION AGGRAVATED14 reports
PAIN IN EXTREMITY14 reports
ASTHENIA13 reports
DIARRHOEA13 reports
OFF LABEL USE13 reports
NEPHROGENIC ANAEMIA12 reports
PNEUMONIA12 reports
PRURITUS12 reports
END STAGE RENAL DISEASE11 reports
INSOMNIA11 reports
MALAISE11 reports
PYREXIA11 reports
VOMITING11 reports
COUGH10 reports
ERYTHEMA10 reports
HYPERPARATHYROIDISM SECONDARY10 reports
PRODUCT DOSE OMISSION ISSUE10 reports
CONSTIPATION9 reports
DECREASED APPETITE9 reports
DRY SKIN9 reports
GAIT DISTURBANCE9 reports
PERIPHERAL SWELLING9 reports
ANXIETY8 reports
BACK PAIN8 reports
DRUG DEPENDENCE8 reports
MEMORY IMPAIRMENT8 reports
MUSCLE SPASMS8 reports
SKIN EXFOLIATION8 reports
TUBULOINTERSTITIAL NEPHRITIS8 reports
URTICARIA8 reports
FULL BLOOD COUNT ABNORMAL7 reports
GASTROOESOPHAGEAL REFLUX DISEASE7 reports
HYPERTENSION7 reports
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES7 reports
PULMONARY EMBOLISM7 reports
PULMONARY FIBROSIS7 reports
RENAL INJURY7 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE7 reports
THROMBOSIS7 reports
WEIGHT DECREASED7 reports
WHEEZING7 reports
ADVERSE DRUG REACTION6 reports
ALOPECIA6 reports
ANAEMIA6 reports
ARTHRALGIA6 reports
ASTHMA6 reports
CHRONIC KIDNEY DISEASE MINERAL AND BONE DISORDER6 reports
DEHYDRATION6 reports
FALL6 reports
FEELING ABNORMAL6 reports
HYPOTENSION6 reports
HYPOXIA6 reports
INFECTION6 reports
LUNG DISORDER6 reports
MUSCULAR WEAKNESS6 reports
MYALGIA6 reports
OEDEMA PERIPHERAL6 reports
PSORIASIS6 reports
SLEEP DISORDER6 reports
SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION6 reports
ABDOMINAL PAIN5 reports
ATRIAL FIBRILLATION5 reports
BURNING SENSATION5 reports
CARDIAC FAILURE CONGESTIVE5 reports
CHILLS5 reports
DEPRESSION5 reports
DRUG DOSE OMISSION5 reports
FLATULENCE5 reports
HAEMOPTYSIS5 reports
HYPOTHYROIDISM5 reports
INFLUENZA5 reports
MUSCULOSKELETAL STIFFNESS5 reports
NEURITIS5 reports
NEUROLOGICAL SYMPTOM5 reports
OBSTRUCTIVE AIRWAYS DISORDER5 reports
PULMONARY ALVEOLAR HAEMORRHAGE5 reports
PULMONARY VASCULITIS5 reports
RESPIRATORY SYMPTOM5 reports
STOMATITIS5 reports
VASCULITIS5 reports
WHITE BLOOD CELL COUNT DECREASED5 reports
ABDOMINAL DISCOMFORT4 reports
ARTERIOSCLEROSIS CORONARY ARTERY4 reports
ARTHRITIS4 reports
BRONCHITIS4 reports
CARDIAC ARREST4 reports
CHEST PAIN4 reports
CONFUSIONAL STATE4 reports

Report Outcomes

Out of 406 classified reports for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE:

Serious 58.9%Non-Serious 41.1%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female228 (58.9%)
Male158 (40.8%)
Unknown1 (0.3%)

Reports by Age

Age 6510 reports
Age 559 reports
Age 708 reports
Age 748 reports
Age 597 reports
Age 667 reports
Age 697 reports
Age 727 reports
Age 757 reports
Age 827 reports
Age 496 reports
Age 506 reports
Age 546 reports
Age 566 reports
Age 606 reports
Age 636 reports
Age 646 reports
Age 716 reports
Age 766 reports
Age 776 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE?

This profile reflects 933 FDA FAERS reports that mention CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE?

Frequently reported terms in FAERS include CHRONIC KIDNEY DISEASE, FATIGUE, RENAL FAILURE, ACUTE KIDNEY INJURY, DRUG INEFFECTIVE, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE?

Labeling and FAERS entries often list Actavis Pharma, Inc. in connection with CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.